Clinical Priority Program-Bone Infection Registry

NCT ID: NCT01677000

Last Updated: 2020-08-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

297 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-06-30

Study Completion Date

2019-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Establish an international registry of over 400 patients with deep infections involving the bone and/or joint from≥20 centers representing all regions of the world with varied hospital and surgeon practice settings to ensure that registry analyses and research reflect typical clinical practice thereby providing optimal guidance for patients, clinicians, and healthcare researchers. Using a data collection platform that minimizes entry burden, collects most information at the time of surgery, and uses Internet technology to minimize data entry. The registry will include:

1. baseline patient attributes;
2. surgical approach, implants and technology;
3. hospital course;
4. surgeon and institutional characteristics;
5. longitudinal patient outcome,
6. post-procedure complications and revisions,
7. serum/tissue/drainage samples.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Establish an international registry with AOCID of over 400 patients with deep infections involving the bone and/or joint from ≥ 20 centers representing all regions of the world with varied hospital and surgeon practice settings to ensure that registry analyses and research reflect typical clinical practice thereby providing optimal guidance for patients, clinicians, and healthcare researchers. Creation of an AOCID Registry for musculoskeletal infection cases will permit better analysis of the causes, contributing factors including patient immune responses, treatments and clinical outcomes of musculoskeletal infections.

* Establish a practice network that includes ≥ 20 geographically distributed centers. These busy practices will be treating patients with varied geographic status to assure balanced representation of diverse patients and practices.
* Establish a Data Coordinating Core team with AOCID using a data collection platform that minimizes entry burden, collects most information at the time of surgery, and uses Internet technology to minimize data entry.

The registry will include:

* baseline patient attributes
* surgical approach, implants and technology
* hospital course
* surgeon and institutional characteristics
* longitudinal patient outcome
* post-procedure complications and revisions
* serum/tissue/drainage samples

* Establish a Statistical Support team with AOCID to implement cutting-edge statistical techniques including the use of hierarchical generalized linear latent and mixed effects models to address the complex structure and longitudinal nature of registry data. Multivariable predictive models for outcome(s) of infection will be developed.
* Establish an Outcomes Measurement Team with AOCID and Investigators from the CPP team to advance the science of infection-specific and global patient-reported outcomes to support efficient data collection of web-based, longitudinal data in this registry and future comparative effectiveness research.
* Develop new assessment tools and conduct research useful to clinical practice. Establish consensus on the definition of treatment failure- characterized as lack of clinically meaningful improvement in infection, pain or physical function following treatment, validate, and refine prediction algorithms for patients at risk for failure.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bone Infection Staphylococcus Aureus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients aged 18 years or older
* Confirmed\* oxacillin-/methicillin-sensitive Staphylococcus aureus (OSSA/ MSSA) or methicillin resistant Staphylococcus aureus (MRSA) infection involving a long bone (ie, femur, tibia, fibula, humerus, radius, ulna, and clavicle) with one (or a combination) of the following:

* Osteomyelitis
* Fracture fixation hardware /prosthetic joint infection
* Infection around an arthroplasty
* Ability to understand the content of the patient information / informed consent form and to participate in the clinical investigation
* Signed written informed consent \* Confirmed either by positive culture from baseline examination or by positive culture from a prior examination of the same surgical site and definitely ongoing infection with Staphylococcus aureus according to the treating surgeon

Exclusion Criteria

* Patients who cannot give informed consent
* Patients who cannot attend the follow up visits
* Recent history of substance abuse (ie, recreational drugs, alcohol) that would preclude reliable assessment
* Prisoner
Minimum Eligible Age

18 Years

Maximum Eligible Age

130 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AO Clinical Investigation and Publishing Documentation

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Stephen L Kates, MD

Role: PRINCIPAL_INVESTIGATOR

University of Richmond

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Missouri Health Care

Columbia, Missouri, United States

Site Status

Unity Hospital

Rochester, New York, United States

Site Status

University of Rochester

Rochester, New York, United States

Site Status

Geisinger Health System

Danville, Pennsylvania, United States

Site Status

University of Richmond, Department of Orthopaedic Surgery

Richmond, Virginia, United States

Site Status

Hospital Italiano de Buenos Aires

Buenos Aires, , Argentina

Site Status

Medizinische Universitaetsklinik Innsbruck

Innsbruck, , Austria

Site Status

Universitair Ziekenhuis Leuven

Leuven, , Belgium

Site Status

Foothills Medical Centre

Calgary, Alberta, Canada

Site Status

Southwestern Hospital Chongqing

Chongqing, Chongqing Municipality, China

Site Status

Affiliated Hospital of Zunyi Medical College

Zunyi, Guizhou, China

Site Status

Beijing University Third Hospital

Beijing, , China

Site Status

Zhejiang Provincial People's Hospital

Hangzhou, , China

Site Status

Queen Mary Hospital

Hong Kong, , China

Site Status

Aarhus University Hospital

Aarhus, , Denmark

Site Status

Berufsgenossenschaftliche Unfallklinik Murnau

Murnau am Staffelsee, Bavaria, Germany

Site Status

Justus-Liebig-Universität

Giessen, , Germany

Site Status

Universitaetsklinikum Regensburg

Regensburg, , Germany

Site Status

Hokkaido University Graduate School of Medicine

Sapporo, Hokkaido, Japan

Site Status

Hamawaki Orthopaedic Hospital

Hiroshima, , Japan

Site Status

Universitätsspital Basel

Basel, Canton of Basel-City, Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Austria Belgium Canada China Denmark Germany Japan Switzerland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CPP Infection Registry

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

RETR(Osteomyelitis)
NCT04936958 UNKNOWN